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Abstract 
Cinnamon (Cinnamomum burmannii) shows anticancer activity in several types of 
cancer cells. The aim of this study is to  observe the cytotoxic activity of cinnamon essential 
oil (CEO) solely and its combination with doxorubicin,  also the  ability  of  the  combination 
to induce apoptosis on T47D breast cancer cells. The CEO was prepared through distillation 
of dry cinnamon bark. Cytotoxic  assay  was performed by using MTT assay and apoptosis 
determination was done by using double staining with ethidium bromide and acridine orange. 
The result showed that CEO exhibited cytotoxic effect on T47D cells with IC50 values of 75 
µg/mL.  Moreover, CEO showed synergist effect with doxorubicin. The lowest combination 
index (CI) with CI values of 0,37 was obtained by combination of doxorubicin-CEO  37.5  
µg/mL-1.25  µM. Treatment with CEO solely and its combination with doxorubicin showed 
apoptosis induction on T47D cells. The results of this  study  indicate  the potency of CEO  
to  be  developed  as co-chemotherapeutic  agent  of  doxorubicin on breast cancer.   
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INTRODUCTION 
 
Cancer is one of the major human 
diseases and causes considerable suffering and 
economic loss worldwide. Breast cancers show 
high incidence over the world and there are 
estimated over 200,000 new cases of breast 
cancer on American women (American Cancer 
Society, 2013). Selective eradication of cancer 
cells is an important goal for cancer 
chemotherapy in the 21
st 
century. 
Chemotherapeutic agent, such as doxorubicin, 
causes several side effect such as depression of 
immune system (Wattanapitayakul, et al., 2005) 
and resistance of cáncer cells (Smith, et al., 
2006). 
Combination of chemotherapy (co-
chemotherapy) is a strategy to make cancer 
therapy become more effective, safe, and 
suppress side effect of  doxorubicin. 
Phytochemicals are potential to be developed as 
anticancer agent (Tyagi, et al., 2004) and 
several compounds could be found in cinnamon 
bark. The active component of cinnamon bark, 
cinnamaldehyde, performes antiproliferative 
activity in several cancer cells such as lung, 
renal, colon, CNS, melanoma, breast, leukemia, 
ovary, and prostate (Lee, et al., 1999). The aim 
of this study is to observe the synergistic effect 
of cinnamon essential oil (CEO) combined with 
doxorubicin in cytotoxic effect and apoptosis 
induction on T47D breast cancer cells. The 
results of this study can be a reference for 
further research of developing CEO as potential 
co-chemotherapeutic agent. 
 
MATERIALS AND METHODS 
 
Cinnamon Essential Oil (CEO) 
Cinnamon bark was obtained from 
Boyolali, Central Java, Indonesia and 
determined in Pharmaceutical Biology 
Laboratory, Faculty of Pharmacy, UGM. The 
barks was dried and chopped, then placed in the 
sample flask.  
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Aquadest was added to the water flask (± 3 L) 
and boiled until 100
o
C. Steam was produced 
under the sample and condensed as distillate.  
 
Cell Culture 
T47D cells was obtained from Prof. 
Tatsuo Takeya (Nara Institute of Science and 
Technology, Japan) and cultured in Dulbecco’s 
modified Eagle’s medium (DMEM; Gibco) 
supplemented with 10% fetal bovine serum 
(FBS; Gibco) and 1% v/v 10,000 units/mL 
penicillin-10,000 μg/ml streptomycin (Gibco) at 
temperature 37°C and with a flow of 5% CO2 . 
 
Cytotoxic Assay  
T47D cells were seeded in 96-well plate 
with 1x10
4
 cells/well and divided into control 
and treatment group. Final concentrations of 
CEO were 50, 100, 150, 200, 300, 400 and  500 
µg/mL while concentration of doxorubicin were 
5, 10, 20, 30, 40, and 50 µM. Concentration 
series of CEO and doxorubicin then diluted in 
culture medium up to the final concentrations. 
After 24 h incubation, culture medium was 
removed and cells were washed using PBS 
(Sigma). Five mg/mL of MTT on PBS (Sigma) 
was diluted by DMEM (1:9) and 100 µL of it 
was added into each well. After incubation for 3 
hours, the reaction was stopped by Sodium 
Dodecyl Sulfate (SDS) 10% in HCL 0.01 N. 
The plate then incubated for one night in room 
condition at dark place. To make sure the 
formazan dissolve, the plate was shaken for 10 
minutes and the absorbance was measured 
using ELISA reader at wave length of 595 nm.  
 
Apoptosis Induction 
 Cover slips were placed on 24 wells 
tissue culture plate. T47D cells were seeded at 
5x10
4 
cells/well. After 24 hours of incubation, 
cells were treated with CEO, doxorubicin, and 
combination of CEO and doxorubicin. After 24 
h of these treatments, cells were washed. Cover 
slips were taken and put on the object glass and 
added by 10 µL 1X working solution ethidium 
bromide-acridin orange (Kasibhatla, et al., 
2006). The treated cells then observed under 
fluorescent microscope.  
 
Data Analysis 
Single Cytotoxicity Assay. Linear 
regression between concentration and % cell 
viability giving the equation y = Bx + A were 
used to calculate IC50 value, that is the 
concentration inhibiting 50% cell proliferation. 
Combinational Cytotoxicity Assay. 
Combinational treatment was evaluated by 
calculating Combination Index (CI) value 
(Reynolds and Maurer, 2005), which has the 
formula as follows. 
 
CI = D1/Dx1 + D2/Dx2 
 
D1 and D2 represent concentrations used 
in combinational treatment, while Dx1 and Dx2 
are single treatment concentration giving the 
same response as D1 and D2, respectively. CI 
value acquired will allow the evaluation of 
CEO’s potency in combinatorial treatment with 
doxorubicin on T47D cells. Interpretation was 
done based on classification listed in Table 1. 
 
 
Table I. Interpretation of CI value representing potency of combinational application 
 
CI Interpretation CI Interpretation 
< 0.1 Very strong synergist 0.9-1.1 Closely additive 
0.1-0.3 Strongly synergist 1.1-1.45 Middle antagonist 
0.3-0.7 Synergist 1.45-3.3 Antagonist 
0.7-0.9 Middle synergist >3.3 Strongly antagonist 
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RESULTS AND DISCUSSION 
 
Effect of Cinnamon Essential Oil (CEO) 
and Doxorubicin on T47D Cells Growth 
CEO with dose range of 50-400 µg/mL 
inhibited cell viability of T47D with IC50 value 
of 75 µg/mL. Along with the increase of CEO 
dose, cell viability was decrease (Fig.1A). CEO 
caused morphological changes in the cells 
(Fig.1C-E) while there were no morphological 
changes in control cells (Fig.1B). 
 
Effect of Cinnamon Essential Oil (CEO) 
Combined with Doxorubicin on T47D 
Cells Growth 
Combination assay was done by 
combining 1/2, 1/4, 1/8, 1/20 IC50 of CEO and 
doxorubicin. The IC50 of CEO was 75 µg/mL 
and IC50 of doxorubicin from the previous 
research was 10 µM (unpublished data). Thus, 
combination dose for CEO were 37.5; 18.75; 
9.375; 3.75 µg/mL and doxorubicin were 5; 2.5; 
1.25; dan 0.5 µM. Combination of CEO and 
doxorubicin decreased cell viability compared 
to doxorubicin alone. Combination index (CI) 
was calculated to evaluate the synergistic effect 
of the combination.  
Results showed nine combinations 
performed synergistic effects, with the CI 
values of less than 0.9 (Reynolds and Maurer, 
2005). The smallest CI showed by combination 
of 37.5 µg/mL CEO and 1.25 µM doxorubicin 
(Table 2). 
Treatment with combination of CEO 
37.5 µg/mL and doxorubicin 1.25 µM reduced 
cell viability significantly different with single 
treatment of each agent. While combination 
treatment with lower concentration of CEO 
(9.375 µg/mL) and doxorubicin did not reduce 
cell viability significantly compound to the 
doxorubicin solely (Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
 
 
 
 
 
 
 
 
Figure 1.  Effect of cinnamon essential oil (CEO) and doxorubicin on T47D cells growth. (A) Graphic 
between CEO dose and T47D cells viability. CEO cytotoxicity expressed by percent cell viability is 
shown as the mean + SE of 3 experiments. IC50 values obtained from the calculation of linear regression 
of concentration vs % viable cells with p<0.05. CEO showed cytotoxicy effect on T47D cells in dose 
dependent manner; (B) Morphology of cells without treatment; (C) treatment of CEO 50 μg/mL; (D) 
treatment of CEO 150 µg/mL; (E) treatment of CEO 300 µg/mL. Arrows (     ) indicates cells undergoing 
morphological changes.  
 
(B) (C) (D) (E) 
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Table 2. Combination Index combination of CEO and doxorubicin 
 
CEO (µg/mL) Doxorubicin (µM) 
0.5 1.25 2.5 5 
3.75 0.52 0.64 0.57 0.50 
9.375 1.59 0.68 0.60 2.68 
18.75 2.81 1.56 1.32 1.17 
37.5 4.90 0.37 0.42 0.53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dox 1.25 µM - + - +  - + - + 
DKM 9.375 µg/mL - - + +  - - - - 
DKM 37.5 µg/mL - - - -  - - + + 
 
Figure 2.  Effect of CEO in combination with doxorubicin on T47D cell viability. Cytotoxic assay was 
done under MTT reaction as described in the methods. Graph represented from the means of 3 
independent experiments and analyzed with ANOVA one way with p<0.05. 
 
 
 
 
 
Effect of CEO and Doxorubicin on 
Apoptosis Induction 
Double staining using ethidium bromide 
and acridin orange was used to observe the 
induction of apoptosis.  Single treatment of 
CEO 37.5 µg/mL and doxorubicin 5 µM 
induced apoptosis of T47D cells. Apoptotic 
induction was indicated by orange fluorescent 
in the nucleus (Fig.3, red arrows). The result 
showed that combination treatment of CEO and 
doxorubin increased the number of cells 
containing red/orange fluorescent. These data 
indicated that the combination of CEO and 
doxorubicin increased the incidence of 
apoptosis. 
 
 
 
* 
* 
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Figure 3.Effect of CEO and doxorubicin on apoptosis. (A) Morphology of cells without treatment; (B) 
treatment of doxorubicin 5 µM; (C) treatment of CEO  37.5 μg/mL; (D) treatment combination of CEO 
37.5  µg/mL  and  doxorubicin  5  μM.  Arrows  (          )  viable  cells  that  has  green fluorescent, arrows   
(           ) apoptosis cells that has orange fluorescent. 
 
 
 
CEO showed cytotoxic effect on breast 
cancer T47D cells. CEO inhibited T47D cells 
growth with IC50 value of 75 µg/mL. 
According to Ueda, et al. (2000), extract with 
IC50 below 100 µg/mL is potential to be 
developed as anticancer agent. CEO also 
increased cytotoxic activity of doxorubicin on 
T47D cells, indicated by cell viability decrease 
compared to doxorubicin treatment solely. This 
mean that when combined with CEO, 
doxorubicin dose could be decreased but gave 
the same effect on cancer cells. 
Synergistic effect of combination of 
CEO and doxorubicin could be done through 
several mechanisms, such as apoptosis 
induction and/or cell cycle modulation. In this 
study, double staining method was done to 
confirmed apoptosis induction by CEO and 
doxorubicin. From this study, combination of 
CEO (37.5 µg/mL) and doxorubicin (5 µM) 
increased apoptosis incidence compared to each 
compound solely. 
Doxorubicin usually need p53 to induce 
apoptosis (Drummond, 2007), while T47D has 
mutant p53. Thus, apoptosis induction on T47D 
is probably through p53-independent pathway. 
Doxorubicin also has been known to activate 
NFκB. NFκB activation leading to expression 
(A) (B) 
(C) (D) 
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of anti-apoptotic protein, such as Bcl-xL (Pahl, 
1999). On the other hand, aqueous extract of 
cinnamon has been known to inhibit NFκB 
activation (Kwon, et al., 2010). By NFκB 
inhibition, expression of anti-apoptotic protein 
could be inhibited. Nevertheless, further 
research has to be done to observe effect of 
CEO and doxorubicin on expression of protein 
related with apoptotic pathway. 
Previous study showed that 
cinnamaldehyde, major compound in 
cinnamon, induced apoptosis through 
mitochondrial permeability transition (MPT) 
(Ka, et al., 2003). Increase of mitochondrial 
membran permeability caused cytochrome c 
excess, then activate caspase 3 and leading to 
apoptosis (Mizutani, et al., 2005).  
But, cytotoxic activity in CEO seems 
likely not only caused by cinnamaldehyde. 
Singh, et al. (2007) reported that aqueous 
cinnamon extract (ACE) showed stronger 
cytotoxic effect compared to cinnamaldehyde 
alone. There are some polyphenol compounds 
that might has synergistic effect with 
cinnamaldehyde. Thus, distillate 
standardization  is  needed  to  be  done  as  
well  as  to  know  more  active  compound  in  
the CEO. 
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